Pfizer Vyndaqel Launch Surprises With An Early Burst Out Of The Gate

The drug outperformed investor expectations, generating $79m in the US in its first full quarter on the market, after Pfizer had set low expectations for the initial launch.

High-energy particles explosion. 3D illustration - Illustration
The launch of Vyndaqel started with a bang. • Source: Shutterstock

Pfizer Inc.'s new rare disease franchise Vyndaqel/Vyndamax (tafamidis) got off to a strong start, surprising investors by generating notable revenues in its first full quarter on the market. Management had set low expectations for initial uptake of the first-in-class transthyretin stabilizer, indicated for treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), because of low diagnosis rates.

Vyndaqel generated $79m in the US and $156m worldwide, the company reported in its third quarter financial report on 29...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip